Instituto de Molestias Cardiovasculares de Tatui

Tatuí, São Paulo 18270-170

2 studies enrolling now · 4 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, COVID-19, Heart Failure, Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Obesity, Overweight, Pneumonia

Studies at this site

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) — Stopped early
• Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) — Completed